These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 20032006

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.
    Barau C, Braun J, Vincent C, Haim-Boukobza S, Molina JM, Miailhes P, Fournier I, Aboulker JP, Vittecoq D, Duclos-Vallée JC, Taburet AM, Teicher E, Agence Nationale de Recherche sur le Sida et les hépatites (ANRS) 148 Study Group.
    Clin Infect Dis; 2014 Oct 15; 59(8):1177-84. PubMed ID: 24992955
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67. Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort.
    Neukam K, Mira JA, Collado A, Rivero-Juárez A, Monje-Agudo P, Ruiz-Morales J, Ríos MJ, Merino D, Téllez F, Pérez-Camacho I, Gálvez-Contreras MC, Rivero A, Pineda JA, HEPAVIR SEG-HEP-2007 Study Group of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
    PLoS One; 2016 Oct 15; 11(2):e0148104. PubMed ID: 26848975
    [Abstract] [Full Text] [Related]

  • 68. Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
    Crespo M, Navarro J, Moreno S, Sanz J, Márquez M, Zamora J, Ocampo A, Iribaren JA, Rivero A, Llibre JM.
    Enferm Infecc Microbiol Clin; 2017 Oct 15; 35(8):493-498. PubMed ID: 27061975
    [Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy.
    Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, Tubiana R, Poynard T, Katlama C, Lombès A, Benhamou Y.
    Hepatology; 2009 Feb 15; 49(2):436-42. PubMed ID: 19085967
    [Abstract] [Full Text] [Related]

  • 74. Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen.
    Cousins D, Topping K, Lee V, Sweeney J, Lawton M.
    Drug Metabol Drug Interact; 2011 Feb 15; 26(3):139-41. PubMed ID: 21980965
    [Abstract] [Full Text] [Related]

  • 75. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
    Vispo E, Fernández-Montero JV, Labarga P, Barreiro P, Soriano V.
    AIDS; 2013 Apr 24; 27(7):1187-8. PubMed ID: 23739226
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.